Retraction of: Structural basis for antagonism by suramin of heparin binding to vaccinia complement protein (Biochemistry (2005) 44:32 (10757-10765) DOI: 10.1021/bi050401x);Structural basis for antagonism by suramin of heparin binding to vaccinia complement protein

Biochemistry

Volumn 44, Issue 32, 2005, Pages 10757-10765

  Ganesh, Vannakambadi K ^a   Muthuvel, Suresh Kumar ^a   Smith, Scott A ^b   Kotwal, Girish J ^b,c   Murthy, Krishna H M ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b University of Louisville School of Medicine   (United States)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ENZYME INHIBITION; GENES; GROWTH KINETICS; PATIENT TREATMENT; TUMORS; VIRUSES;

FIBROBLASTS; HEPARIN BINDING; TYROSINE PHOSPHATASES; VIRAL ENVELOPE PROTEINS;

PROTEINS;

FIBROBLAST GROWTH FACTOR; HEPARIN; PROTEIN TYROSINE PHOSPHATASE; SURAMIN; UNCLASSIFIED DRUG; VACCINIA COMPLEMENT PROTEIN; VIRUS PROTEIN;

ANGIOGENESIS; ARTICLE; CANCER CHEMOTHERAPY; CONCENTRATION RESPONSE; DRUG DESIGN; DRUG PROTEIN BINDING; DRUG STRUCTURE; ENZYME INHIBITION; GEOMETRY; NONHUMAN; PRIORITY JOURNAL; PROTEIN STRUCTURE; UPREGULATION; VACCINIA VIRUS; VIRUS ENVELOPE;

VACCINIA; VACCINIA VIRUS;

EID: 23844501931     PISSN: 00062960     EISSN: 15204995     Source Type: Journal    
DOI: 10.1021/acs.biochem.8b00955     Document Type: Erratum

References (52)

1. Mirza, M. R., Jakobsen, E., Pfeiffer, P., Lindebjerg-Clasen, B., Bergh, J., and Rose, C. (1997) Suramin in non-small cell lung cancer and advanced breast cancer. Two parallel phase II studies, Acta Oncol. 36, 171-174.
2. Small, E. J., Meyer, M., Marshall, M. E., Reyno, L. M., Meyers, F. J., Natale, R. B., Lenehan, P. F., Chen, L., Slichenmyer, W. J., and Eisenberger, M. (2000) Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone, J. Clin. Oncol. 18, 1440-1450.
3. Dreicer, R., Smith, D. C., Williams, R. D., and See, W. A. (1999) Phase II trial of suramin in patients with metastatic renal cell carcinoma, Invest. New Drugs 17, 183-186.
4. Falcone, A., Pfanner, E., Brunetti, I., Allegrini, G., Lencioni, M., Galli, C., Masi, G., Danesi, R., Antonuzzo, A., Del Tacca, M., and Conte, P. F. (1998) Suramin in combination with 5-fluorouracil (5-FU) and leucovorin (LV) in metastatic colorectal cancer patients resistant to 5-FU+LV-based chemotherapy, Tumori 84, 666-668.
5. Nok, A. J. (2003) Arsenicals (melarsoprol), pentamidine and suramin in the treatment of human African trypanosomiasis, Parasitol. Res. 90, 71-79.
6. Aguilar, J. S., Rice, M., and Wagner, E. K. (1999) The polysulfonated compound suramin blocks adsorption and lateral difusion of herpes simplex virus type-1 in vero cells, Virology 258, 141-151.
7. Chen, Y., Maguire, T., Hileman, R. E., Fromm, J. R., Esko, J. D., Linhardt, R. J., and Marks, R. M. (1997) Dengue virus infectivity depends on envelope protein binding to target cell heparan sulfate, Nat. Med. 3, 866-871.
8. Zhang, Y. L., Keng, Y. F., Zhao, Y., Wu, L., and Zhang, Z. Y. (1998) Suramin is an active site-directed, reversible, and tight-binding inhibitor of protein-tyrosine phosphatases, J. Biol. Chem. 273, 12281-12287.
9. Ornitz, D. M. (2000) FGFs, heparan sulfate and FGFRs: complex interactions essential for development, Bioessays 22, 108 -112.
10. Liekens, S., De Clercq, E., and Neyts, J. (2001) Angiogenesis: regulators and clinical applications, Biochem. Pharmacol. 61, 253-270.
11. Murakami, M. T., Gava, L. M., Zela, S. P., Arruda, E. Z., Melo, P. A., Gutierrez, J. M., and Ami, R. K. (2004) Crystallization and preliminary X-ray diffraction analysis of suramin, a highly charged polysulfonated naphthylurea, complexed with a myotoxi-cPLA2 from Bothrops asper venom, Biochim. Biophys. Acta 1703, 83-85.
12. Kaur, M., Reed, E., Sartor, O., Dahut, W., and Figg, W. D. (2002) Suramin's development: what did we learn?. Invest. New Drugs 20, 209-219.
13. Kotwal, G. J., and Moss, B. (1988) Vaccinia virus encodes a secretory polypeptide structurally related to complement control proteins, Nature 335, 176-178.
14. Kotwal, G. J., Issacs, S. T., McKenzie, R., Frank, M. M., and Moss, B. (1990) Inhibition of the complement cascade by the major secretory protein of vaccinia virus, Science 250, 827-830.
15. Bork, P., Downing, A. K., Kieffer, B., and Campbell, I. D. (1995) Structure and distribution of modules in extracellular proteins, Q. Rev. Biophys. 29, 119-167.
16. Wiles, A. P., Shah, G., Bright, J., Perczel, A., Campbell, I. D., and Barlow, P. (1997) NMR studies of a viral protein that mimics regulators of complement activation, J. Mol. Biol. 272.
17. Kotwal, G. J., Reynolds, D., Keeling, K., Howard, J., and Justus, D. E. (1998) in 10th International Congress of Immunology, New Delhi, India (Talwar, G. P., and Nath, I., Eds.) pp 315-320, Monduzzi Editore Publishing, Bologna, Italy.
18. Pangburn, M. K., Pangburn, K. L. W., Koistinen, V., Meri, S., and Sharma, A. K. (2000) Molecular mechanisms of target recognition in an innate immune system: interactions among factor H, C3b and target in the alternative pathway of human complement, J. Immunol. 164, 4742-4751.
19. Kotwal, G. J. (2000) Poxvirus mimicry of complement and chemokine system components: what is the end game?, Immunol. Today 21, 243-248.
20. Cooper, N. R. (1991) Complement evasion strategies of microorganisms, Immunol. Today 12, 327-331.
21. Smith, S. A., Sreenivasan, R., Krishnasamy, G., Judge, K. W., Murthy, K. H., Arjunwadkar, S. J., Pugh, D. R., and Kotwal, G. J. (2003) Mapping of regions within the vaccinia virus complement control protein involved in dose-dependent binding to key complement components and heparin using surface plasmon resonance, Biochim. Biophys. Acta 1650, 30-39.
22. Ganesh, V. K., Smith, S. A., Kotwal, G. J., and Murthy, K. H. (2004) Structure of vaccinia complement protein in complex with heparin and potential implications for complement regulation, Proc. Natl. Acad. Sci. U.S.A. 101, 8924-8929.
23. Murthy, K. H. M., Smith, S. A., Ganesh, V. K., Judge, K. W., Mullin, N., Barlow, P. N., Ogata, C. O., and Kotwal, G. J. (2001) Crystal structure of a complement control protein that regulates both pathways of complement activation and binds heparan sulfate proteoglycans, Cell 104, 301-311.
24. Smith, S. A., Mullin, N. P., Parkinson, J., Shchelkunov, S. N., Totmentin, A. V., Loparev, V. N., Srisatjaluk, R., Reynolds, D. N., Keeling, K. L., Justus, D. E., Barlow, P. N., and Kotwal, G. J. (2000) Surface exposed conserved K/R-X-K/R sites and positive charge on poxviral complement control proteins contribute to heparin binding and to inhibition of molecular interactions with human endothelial cells: a novel mechanism for evasion of host defense, J. Virol. 74, 5659-5666.
25. Otwinowski, Z., and Minor, W. (1997) in Methods in Enzymology (Carter, C. W., and Sweet, R. M., Eds.) pp 307-326, Academic Press, New York.
26. Read, R. J. (2001) Pushing the boundaries of molecular replacement with maximum likelihood, Acta Crystallogr., Sect. D: Biol. Crystallogr. 57, 1373-1382.
27. CCP4 (1993) The CCP4 suite: programs for protein crystallography, Acta Crystallogr. D50, 760-763.
28. Jones, T. A., Zou, J. Y., Cowans, S. W., and Kjeldgaard, M. (1991) Improved methods for building protein models in electron density and location of errors in these models, Acta Crystallogr. A47, 110-119.
29. Cowtan, K., and Main, P. (1998) Miscellaneous algorithms for density modification, Acta Crystallogr., Sect. D: Biol. Crystallogr. 54 (Part 4), 487-493.
30. Brunger, A. T., Adams, P. D., Clore, G. M., DeLano, W. L., Gros, P., Grosse-Kunstleve, R. W., Jiang, J. S., Kuszewski, J., Nilges, M., Pannu, N. S., Read, R. J., Rice, L. M., Simonson, T., and Warren, G. L. (1998) Crystallography & NMR system: A new software suite for macromolecular structure determination, Acta Crystallogr., Sect. D: Biol. Crystallogr. 54 (Part 5), 905-921.
31. Nicholls, A., Sharp, K. A., and Honig, B. (1991) Protein folding and association: insights from the interfacial and thermodynamic properties of hydrocarbons, Proteins: Struct., Funct., Genet. 11, 281-289.
32. Carson, M. C. (1997) in Methods in Enzymology (Carter, C. W., and Sweet, R. M., Eds.) pp493-505, Elsevier Science, New York.
33. DiGabriele, A. D., Lax, I., Chen, D. I., Svahn, C. M., Jaye, M., Schlessinger, J., and Hendrickson, W. A. (1998) Structure of a Heparin-Linked Biologically Active Dimer of Fibroblast Growtf Factor, Nature 393, 812-817.
34. Polenova, T., Iwashita, T., Palmer, A. G., III, and McDermott, A. E. (1997) Conformation of the trypanocidal pharmaceutical suramin in its free and bound forms: transferred nuclear overhauser studies, Biochemistry 36, 14202-14217.
35. Dos Santos, H. F., O'Malley, P. J., and De Almeida, W. B. (1998) Gas phase and water solution conformational analysis of the herbicide diuron (DCMU): an ab initio study, Theor. Chem. Acc. 99, 301-311.
36. Olsen, S. K., Garbi, M., Zampieri, N., Eliseenkova, A. V., Ornitz, D. M., Goldfarb, M., and Mohammadi, M. (2003) Fibroblast growth factor (FGF) homologous share structural but not functional homology with FGFs, J. Biol. Chem. 278, 34226-34236.
37. Schlessinger, J., Plotnikov, A. N., Ibrahimi, O. A., Eliseenkova, A. V., Yeh, B. K., Yayon, A., Linhardt, R. J., and Mohammadi, M. (2000) Crystal structure of a ternary FGF-FGFR-heparin complex reveals a dual role for heparin in FGFR binding and dimerization, Mol. Cell 6, 743-750.
38. Pellegrini, L., Burke, D. F., von Delft, F., Mulloy, B., and Blundell, T. L. (2000) Crystal structure of fibroblast growth factor receptor ectodomain bound to ligand and heparin, Nature 407, 1029-1034.
39. Ibrahimi, O. A., Yeh, B. K., Eliseenkova, A. V., Zhang, F., Olsen, S. K., Igarashi, M., Aaronson, S. A., Linhardt, R. J., and Mohammadi, M. (2005) Analysis of mutations in fibroblast growth factor (FGF) and a pathogenic mutation in FGF receptor (FGFR) provides direct evidence for the symmetric two-end model for FGFR dimerization, Mol. Cell. Biol. 25, 671-684.
40. Pellegrini, L. (2001) Role of heparan sulfate in fibroblast growth factor signalling: a structural view, Curr. Opin. Struct. Biol. 11, 629-634.
41. Stein, C. A. (1993) Suramin: a novel antineoplastic agent with multiple potential mechanisms of action, Cancer Res. 53, 2239-2248.
42. Botta, M., Manetti, F., and Corelli, F. (2000) Fibroblast growth factors and their inhibitors, Curr. Pharm. Des. 6, 1897-1924.
43. Middaugh, C. R., Mach, H., Burke, C. J., Volkin, D. B., Dabora, J. M., Tsai, P. K., Bruner, M. W., Ryan, J. A., and Marfia, K. E. (1992) Nature of the interaction of growth factors with suramin, Biochemistry 31, 9016-9024.
44. Fernandez-Tornero, C., Lozano, R. M., Redondo-Horcajo, M., Gomez, A. M., Lopez, J. C., Quesada, E., Uriel, C., Valverde, S., Cuevas, P., Romero, A., and Gimenez-Gallego, G. (2003) Leads for development of new naphthalenesulfonate derivatives with enhanced antiangiogenic activity: crystal structure of acidic fibroblast growth factor in complex with 5-amino-2-naphthalene sulfonate, J. Biol. Chem. 278, 21774-21781.
45. Lozano, R. M., Jimenez, M., Santoro, J., Rico, M., and Gimenez-Gallego, G. (1998) Solution structure of acidic fibroblast growth factor bound to 1,3,6-naphthalenetrisulfonate: a minimal model for the anti-tumoral action of suramins and suradistas, J. Mol. Biol. 281, 899-915.
46. Garson, J. A., Lubach, D., Passas, J., Whitby, K., and Grant, P. R. (1999) Suramin blocks hepatitis C binding to human hepatoma cells in vitro, J. Med. Virol. 57, 238-242.
47. Carfi, A., Willis, S. H., Whitbeck, J. C., Krummenacher, C., Cohen, G. H., Eisenberg, R. J., and Wiley, D. C. (2001) Herpes simplex virus glycoprotein D bound to the human receptor HveA, Mol. Cell 8, 169-178.
48. Modis, Y., Ogata, S., Clements, D., and Harrison, S. C. (2003) A ligand-binding pocket in the dengue virus envelope glycoprotein, Proc. Natl. Acad. Sci. U.S.A. 100, 6986-6991.
49. Modis, Y., Ogata, S., Clements, D., and Harrison, S. C. (2004) Structure of the dengue virus envelope protein after membrane fusion, Nature 427, 313-319.
50. Manetti, F., Cappello, V., Botta, M., Corelli, F., Mongelli, N., Biasoli, G., Borgia, A. L., and Ciomei, M. (1998) Synthesis and binding mode of heterocyclic analogues of suramin inhibiting the human basic fibroblast growth factor, Bioorg. Med. Chem. 6, 947-958.
51. Mohan, P., Hopfinger, A. J., and Baba, M. (1989) Naphthalene-disulfonic Acid derivatives as potential anti-HIV agents: chemistry, biology and molecular modeling of their inhibition of reverse transcriptase, Antiviral Chem. Chemother. 2, 215-222.
52. Wallace, A. C., Laskowski, R. A., and Thornton, J. M. (1995) A program to generate schematic diagrams of protein-ligand interactions, Protein Eng. 8, 127-134.